OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Optina Diagnostics

2 Projects | 1 Researchers | $3,658,500 Invested

2023

Optina Diagnostics

Jean-Philippe Sylvestre, PEng, PhD

Clinical value evaluation of the awAIr(TM)-CAS test based on hyperspectral retinal imaging

  • Funding Amount: $1,523,500
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Other
  • Status: Active

2021

Optina Diagnostics

Jean-Philippe Sylvestre, PEng, PhD

Validation of the Retinal Deep Phenotyping(TM) platform for the detection of the likely cerebral amyloid status to aid in the diagnosis of Alzheimer’s disease

  • Funding Amount: $2,135,000
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: zzAbeta
  • Status: Active